Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cholera vaccine (inactivated, oral) (Valneva)
- Development stage
- Phase 4
- Lead developer
- Valneva
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Dukoral is an oral inactivated vaccine used for active immunization against disease caused by *Vibrio cholerae* serogroup O1. It contains killed whole *V. cholerae* O1 bacteria (including both Inaba and Ogawa serotypes and El Tor and Classical biotypes) and a recombinant non-toxic B subunit of the cholera toxin. The vaccine works by inducing antibodies in the intestine that target both the bacterial components and the toxin B subunit, preventing colonization of *V. cholerae* O1 on the intestinal wall as well as neutralizing the effects of cholera toxin. This immune response helps protect against infection by blocking attachment of bacteria and toxins to gut cells[1][2][5]. Dukoral is primarily indicated for travelers visiting areas where there is a risk of epidemic or endemic cholera[1][2]. It also provides some cross-protection against diarrhea caused by enterotoxigenic *Escherichia coli* (ETEC) producing heat-labile enterotoxin due to structural similarity with the cholera toxin B subunit[6].
- Brand names
- Dukoral
- Other names
- cholera vaccine (inactivated, oral)
02
Targets
CTBS (Cholera toxin B subunit)LTB (Heat-labile enterotoxin B subunit)O1 antigen (Vibrio cholerae O1 surface antigen)LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on cholera vaccine (inactivated, oral) (Valneva).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cholera vaccine (inactivated, oral) (Valneva).